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Abstract
 
We have previously demonstrated that interleukin (IL)-10–deficient (IL-10 knockout [KO])
but not wild-type (WT) mice develop colitis after infection with 
 
Helicobacter hepaticus
 
. Here, we
show that infected recombination activating gene (RAG) KO mice develop intestinal inflammation
after reconstitution with CD4
 
  
 
T cells from IL-10 KO animals and that the cotransfer of CD4
 
 
 
T cells from 
 
H. hepaticus
 
–infected but not uninfected WT mice prevents this colitis. The
disease-protective WT CD4
 
  
 
cells are contained within the CD45RB
 
low 
 
fraction and unexpectedly
were found in both the CD25
 
  
 
and the CD25
 
  
 
subpopulations of these cells, their frequency
being higher in the latter. The mechanism by which CD25
 
  
 
and CD25
 
  
 
CD45RB
 
low 
 
CD4
 
 
 
cells block colitis involves IL-10 and not transforming growth factor (TGF)-
 
 
 
, as treatment
with anti–IL-10R but not anti–TGF-
 
 
 
 monoclonal antibody abrogated their protective effect.
In vitro, CD45RB
 
low 
 
CD4
 
  
 
cells from infected WT mice were shown to produce IL-10 and
suppress interferon-
 
  
 
production by IL-10 KO CD4
 
  
 
cells in an 
 
H. hepaticus
 
 antigen–specific
manner. Together, our data support the concept that 
 
H. hepaticus
 
 infection results in the induction
in WT mice of regulatory T cells that prevent bacteria-induced colitis. The induction of
such cells in response to gut flora may be a mechanism protecting normal individuals
against inflammatory bowel disease.
Key words: inﬂammatory bowel disease • regulatory T cells • intestinal ﬂora • CD25 • 
immunoregulation
 
Introduction
 
Experimental models have established a crucial role for micro-
bial flora in the induction of inflammatory bowel disease
(IBD).
 
* 
 
For example, several strains of immunocompromised
mice and rats known to develop intestinal inflammation when
housed in conventional animal facilities show minimal or no
disease when reared under specific pathogen-free (SPF) or
germfree (GF) conditions (1–6). A requirement for gut flora
has also been demonstrated for the development of colitis in
the well-established CD4/SCID transfer model of IBD in
which intestinal inflammation is induced in T cell–deficient
recipients by transfer of splenic CD45RB
 
hi 
 
CD4
 
  
 
cells from
naive WT mice (7, 8). Thus, in this model, no inflammation is
observed upon the transfer of CD45RB
 
hi 
 
CD4
 
  
 
cells to T
cell–deficient mice raised under GF conditions (9) or with a
reduced bacterial load (10). Moreover, the pathogenic CD4
 
 
 
cells do not have to be primed by gut flora before cell transfer,
as CD45RB
 
hi 
 
cells from GF mice induce disease upon transfer
to flora-containing SCID mice (11). Although the etiology of
the two major chronic intestinal inflammatory diseases of man,
Crohn’s disease and ulcerative colitis, is largely unknown
and believed to be multifactorial, several reports have also
implicated a role for intestinal flora in the development of
these diseases (12–14).
Considering the vast number of bacteria in the intestine,
there must exist mechanisms by which immune responses
to these microbes are controlled so that a state of chronic
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Helicobacter hepaticus
 
 Ag; SPF, specific
pathogen-free; Treg, T regulatory. 
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inflammation is prevented from developing in the gut.
General mechanisms believed to play a role in protection
against autoimmunity, such as T cell deletion, T cell an-
ergy, and immunologic ignorance, could also potentially
contribute to protection against unwanted immune re-
sponses in the gut. In addition, the presence in normal
mice of T regulatory (Treg) cells able to prevent the devel-
opment of intestinal inflammation has been demonstrated.
Thus, the administration of CD45RB
 
low 
 
CD4
 
  
 
cells to T
cell–deficient mice along with the pathogenic CD45RB
 
hi
 
population leads to complete inhibition of colitis develop-
ment (7, 15). These Treg cells block colitis though a mech-
anism involving TGF-
 
  
 
and IL-10 (16, 17), and recent re-
ports have further established that the CD4
 
  
 
Treg cells
inhibiting disease are predominantly found within the
CD25
 
  
 
CD45RB
 
low 
 
population (18, 19).
We have previously demonstrated that SPF IL-10 KO
mice experimentally infected with 
 
Helicobacter hepaticus
 
 de-
velop severe inflammation in the cecum and colon, a dis-
ease associated with a Th1-type cytokine response by me-
senteric lymph node (MLN) cells stimulated in vitro with
soluble 
 
H. hepaticus
 
 Ag (SHelAg; references 20 and 21). In
contrast, WT mice do not develop intestinal inflammation
after inoculation with this bacterium and their MLN cells
instead produce IL-10 in response to SHelAg (20). These
results suggested that infected WT mice mount a disease-
protective CD4
 
  
 
T cell response to the bacterium, possibly
a Treg type of response that prevents the development of
colitis in these animals.
In this study, we have characterized the phenotype and
mode of action of the CD4
 
  
 
T cells in 
 
H. hepaticus
 
–infected
WT animals that protect against disease. Using a modification
of the CD4/SCID IBD model, we induced colitis in 
 
H. he-
paticus
 
–infected RAG KO animals by the transfer of CD4
 
  
 
T
cells from infected colitic IL-10 KO mice and then analyzed
the disease-protective effect of the cotransfer of various
CD4
 
  
 
cell populations from WT mice. We found that
CD25
 
  
 
CD45RB
 
low 
 
and, to a much lesser extent, CD25
 
 
 
CD45RB
 
low 
 
CD4
 
  
 
cells from 
 
H. hepaticus
 
–infected WT mice
block colitis development and that this protection is depen-
dent on IL-10. Importantly, similar populations of CD4
 
 
 
cells derived from uninfected WT animals did not block dis-
ease development. The disease-protective cells are distinct
from conventional Th2 lymphocytes and instead closely re-
semble the in vitro–generated CD4
 
  
 
IL-10–producing Treg
cells recently described (22–24). Taken together, our results
suggest the involvement of bacteria-primed Treg cells in pre-
vention of IBD in normal individuals.
 
Materials and Methods
 
Experimental Animals and Infections.
 
6–16-wk-old female SPF
C57BL/10 IL-10 KO (backcrossed to the 10
 
th 
 
generation),
C57BL/10 (CD45.2
 
 
 
), C57BL/6.SJL (CD45.1
 
 
 
), C57BL/6 IL-4
KO (backcrossed to the 12
 
th 
 
generation), C57BL/10 RAG-2
KO, and C57BL/10 RAG-2/IL-10 double KO (provided by T.
Wynn, NIAID, NIH, Bethesda, MD) mice were obtained from
Taconic Farms. The animals tested negative for antibodies to spe-
cific murine viruses and were free of 
 
Helicobacter
 
 species as assessed
by PCR. Animals were housed in sterile microisolator cages with
autoclaved bedding, food, and water at the animal facility at the
NIAID in accordance with the Guide for the Care and Use of
Laboratory Animals (25) under an animal study proposal ap-
proved by the NIAID Animal Care and Use Committee.
Mice were inoculated intragastrically with 0.5 ml of an 
 
H. he-
paticus 
 
suspension (standard Frederick isolate 1A; references 26
and 27) prepared to a McFarland turbidity standard of 1.0 in PBS
representing 2.45 
 
  
 
10
 
9 
 
CFU/ml. Age-matched uninfected ani-
mals were included as controls.
 
Bacterial Ag Preparation.
 
SHelAg was prepared from cultures of
 
H. hepaticus
 
 as previously described (20, 21). SHelAg was boiled for
5 min, a procedure shown to have no effect on the ability of the Ag
to activate T cells (unpublished data), and stored at 
 
 
 
40
 
 
 
C until use.
 
Cell Purifications.
 
CD4
 
  
 
cells were purified from the MLNs of
naive or 5–21-wk infected WT, IL-10 KO, or IL-4 KO mice by
negative selection using CD4 columns (R&D Systems). The
CD4
 
  
 
cells were generally 
 
 
 
95% pure (range 91–98%) as analyzed
by flow cytometry. For purification of CD45RB
 
high
 
, CD45RB
 
low
 
,
CD25
 
 
 
, and CD25
 
  
 
subpopulations of CD4
 
  
 
cells, MLNs were
stained with anti–CD4-PE (clone RM4-5) or anti–CD4-Cy-
Chrome (RM4-5), anti–CD45RB-FITC (16A), anti–CD25-
biotin (7D4), and streptavidin-PE (all from BD Biosciences), and
sorted on a FACSVantage™ SE or a FACStarPlus™ SE (Becton
Dickinson). In some experiments, MLNs were passed over a CD4
column before staining and sorting. The sorted subpopulations of
CD4
 
  
 
cells were 
 
 
 
99% pure. The CD45RB
 
low 
 
and CD45RB
 
hi
 
cells were collected after gating on 15–20% of the dimmest and
 
 
 
50% of the brightest CD4
 
  
 
cells, respectively.
For APC, CD11c
 
  
 
dendritic cells (DCs) were purified from the
spleens of naive IL-10 KO mice using anti-CD11c MACS micro-
beads (Miltenyi Biotech). The CD11c
 
  
 
DCs were 
 
 
 
90% pure.
 
Cell Transfers to RAG KO Mice and In Vivo mAb Treatment.
 
MLN CD4
 
  
 
cells or subpopulations thereof (3–4 
 
  
 
10
 
5
 
/mouse
or as indicated) were transferred intravenously to naive or 2–4-d
 
H. hepaticus
 
–infected RAG KO mice. Mice receiving no cells
were included as controls. 8–52 d after cell transfer, mice were
killed and intestinal tissues were collected for histologic analysis.
In some experiments, mice were injected intraperitoneally 1 d
after cell transfer and then each week for 4 wk with 2 mg anti–
TGF-
 
  
 
(mAb 2G75A9, anti-TGF-
 
 
 
1,2,3
 
), 1 mg anti–IL-10R
(1B1.3a), or control mAb GL113 (anti–
 
 
 
-galactosidase) in 0.5 ml
PBS. In a separate experiment, mice were given 2 mg anti–TGF-
 
 
 
twice a week for 2 wk. The anti–TGF-
 
  
 
mAb was purified from
ascites by ion exchange chromatography. The anti–IL-10R and
control mAb were purified from ascites by two sequential 50%
ammonium sulfate precipitations.
 
Pathology and Immunohistochemistry.
 
Tissues were fixed in
Bouin’s fixative, embedded in paraffin, sectioned at 5 
 
 
 
m, and
stained with hematoxylin and eosin (H&E). A longitudinal sec-
tion of the entire cecum and a cross section of the ascending co-
lon 
 
 
 
1 cm from the cecum were made. Sections were evaluated
in a blinded fashion by the same pathologist, A.W. Cheever, and
an average score for the whole section was assigned based on a
0–4
 
  
 
scoring system with emphasis on the number of infiltrating
cells for the lamina propria, the submucosa, and the serosa (21).
For the lamina propria and submucosa, a score of 1
 
  
 
indicated
the equivalent of a single layer of infiltrating cells throughout the
section and 4
 
  
 
indicated 
 
 
 
4 cell layers. In addition, crypt ab-
scesses and ulcers were each given a score from 0 to 4. A total
score was calculated by adding the individual scores, meaning
that the maximum total score was 20. Hyperplasia was evaluated 
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as mucosal thickness using an ocular micrometer. Staining of co-
lonic tissues for CD3
 
  
 
T cells was performed as previously de-
scribed (20, 21).
 
Cell Cultures and Cytokine Assays.
 
Cells were cultured in
complete tissue culture medium (RPMI 1640 with 10% heat-
inactivated FCS, 100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin,
2 mM glutamine, 20 mM Hepes, 1 mM sodium pyruvate, 0.1
mM nonessential amino acids, and 50 
 
 
 
M 2-ME) and 5% CO
 
2 
 
at
37
 
 
 
C. CD4
 
  T cells (105/well) from infected IL-10 KO mice
were cultured in 96-well round-bottomed plates (0.2 ml/well)
with CD11c  DC (4   104/well) from naive IL-10 KO animals
as APC, 5  g/ml SHelAg, and indicated numbers of CD45RBlow
CD4  cells from naive or infected WT mice for 72 h.
CD45RBlow CD4  cells (2   105/well) from naive or infected
WT mice were cultured in 96-well round-bottomed plates (0.2
ml/well) with CD11c  DCs (4   104/well) from naive IL-10
KO animals as APC, 5  g/ml SHelAg, and 20 U/ml human rIL-2
(Chiron Corp.) for 72 h. IL-2 was added to cultures as it has been
shown to be necessary for revealing the responsiveness of some
CD45RBlow populations (28).
Supernatants were analyzed for IFN-  and IL-10 by ELISA
using mAb from BD Biosciences.
Intracellular Cytokine Staining. Analyses of intracellular cyto-
kine expression were performed on cells from the same SHelAg-
stimulated cultures used for cytokine secretion assays as previously
described (29). In brief, cells were incubated for an additional 18 h
in fresh medium containing 10 U/ml of rIL-2 added to replace
the culture supernatant collected at 72 h. Thereafter, cells were
stimulated with 1  g/ml PMA and 1 ng/ml ionomycin for 4.5 h
with the addition of 10  g/ml brefeldin A (all from Sigma-
Aldrich) during the last 2 h. Intracellular staining was then
performed as previously described (29) using anti–IL-10–PE
(JES5-16E3) and anti–IFN- –FITC (XMG1.2; both from BD
Biosciences). Cell fluorescence was measured using a FACScan™
(Becton Dickinson) and the data were analyzed using Cell
Quest™ software (Becton Dickinson).
Statistical Analysis. Colitis scores were compared using the
nonparametric Mann-Whitney U test and differences were con-
sidered statistically significant with P   0.05.
Results
Transfer of CD4  T Cells from IL-10 KO Mice Results in
Colitis in H. hepaticus–infected but Not Uninfected RAG KO
Recipients. We have previously shown that SPF-reared
IL-10 KO mice develop a Th1 cytokine-associated colitis
after experimental infection with H. hepaticus (20, 21). In
contrast, H. hepaticus–inoculated WT mice are free of dis-
ease and mount a T cell–dependent IL-10 response to the
bacterium (20), suggesting the development of a disease-
protective CD4  T cell response. To characterize this pro-
tective T cell response in WT mice, we used a modifica-
tion of the CD4/SCID transfer model of colitis involving
experimental infection with bacteria in which disease is in-
duced in H. hepaticus–infected RAG KO recipients by the
transfer of CD4  cells from infected colitic IL-10 KO mice.
After inoculation with H. hepaticus, RAG KO mice on a
C57BL/10 background showed no or minimal signs of in-
testinal inflammation when examined up to 34 wk after in-
fection (Fig. 1, A and B, and not depicted). However, if
2–4-d infected RAG KO mice were reconstituted with
MLN CD4  cells from infected IL-10 KO animals, inflam-
mation developed in the large intestine (colitis) including
the cecum (typhlitis) within 1 wk, gradually increasing over
a 4-wk period (Fig. 1 A). Similar results were observed
Figure 1. H. hepaticus–infected but not naive RAG KO mice develop
intestinal inflammation after reconstitution with CD4  T cells from IL-10
KO mice. (A) Uninfected or H. hepaticus–infected RAG KO mice were
inoculated intravenously with 3   105 CD4  cells from the MLNs of 11-wk
infected IL-10 KO mice, and intestinal pathology was analyzed 8, 15, 22,
and 29 d later (solid bars). Naive and infected RAG KO animals receiving
no cells were analyzed in parallel (open bars). Bars represent mean cecal
histology scores   SD of three or four mice per group. *, P   0.05 compared
with infected mice receiving no cells. (B–D) Histology of ceca of rep-
resentative sections from the mice shown in A analyzed 29 d after cell
transfer: (B) infected RAG KO without cell transfer; (C) infected RAG
KO receiving CD4  cells from infected IL-10 KO mice; or (D) uninfected
RAG KO receiving CD4  cells from infected IL-10 KO mice. Crypt
abscesses (solid arrows), ulcer (open arrow). H&E staining. Bar, 200  m.508 Bacteria-induced Regulatory T Cells Suppress Colitis
when CD4  cells from naive IL-10 KO mice were trans-
ferred to infected RAG KO recipients (unpublished data), a
result we interpret as reflecting the sensitization of the na-
ive transferred CD4  cells by H. hepaticus in the infected re-
cipients. The colitis observed in the RAG KO recipients
was characterized by mucosal hyperplasia and inflammatory
cell infiltrates in the lamina propria, submucosa, and serosa,
as well as by the presence, in severe cases, of crypt abscesses
and ulcers (Fig. 1 C). Importantly, when uninfected RAG
KO mice were given IL-10 KO CD4  cells, no inflamma-
tion was observed in the same time period (Fig. 1, A and
D). These results demonstrate a critical role for both T cells
and the Helicobacter organism in disease induction.
CD45RBlow CD4  Cells from H. hepaticus–infected WT
Mice Protect RAG KO Animals from Colitis Induced by IL-10
KO CD4  Cells plus Bacterial Infection. Next, we investi-
gated whether we could protect the IL-10 KO T cell re-
constituted, infected RAG KO mice from disease by
cotransfer of WT cells. As shown in Fig. 2 A, whereas in-
fected RAG KO hosts receiving IL-10 KO CD4  cells
alone developed colitis, animals receiving a 1:1 mixture of
MLN CD4  cells from IL-10 KO and infected WT mice
did not develop intestinal inflammation. If the WT CD4 
cells originated from uninfected (naive) WT mice, how-
ever, no protection was observed (Fig. 2 A). In fact, the
transfer of naive WT CD4  cells alone induced colitis in
the infected T cell–deficient mice, whereas CD4  cells ob-
tained from infected WT animals did not induce disease in
these recipients. Whereas minimal inflammation was ob-
served in infected T cell–deficient mice with no cell trans-
fer (Fig. 3 A), infected RAG KO recipients of IL-10 KO
CD4  lymphocytes displayed large numbers of cells infil-
trating the intestine (Fig. 3 B). Co-transfer of infected but
not naive WT CD4  cells blocked the accumulation of
these inflammatory infiltrates (Fig. 3, C and D).
The disease-protective effect of CD4  cells from infected
WT mice was not due to the clearance of H. hepaticus in
the recipients. Although no accurate methods exist for the
direct quantification of bacterial colonization of intestinal
tissue by this pathogen, when analyzed by culture and H.
hepaticus–specific PCR, fecal samples from animal groups
receiving IL-10 KO CD4  cells plus CD4  cells from ei-
ther infected or uninfected WT mice were both shown to
be clearly positive for the organism (unpublished data).
To further characterize the disease-protective CD4 
cells, we purified by cell sorting the CD45RBhi  and
CD45RBlow CD4  populations from infected WT mice
and analyzed the ability of these cells to block colitis. Con-
sistent with previous findings in the SCID IBD model (7,
15), CD45RBlow cells from infected WT mice completely
protected the H. hepaticus–infected RAG KO recipients
from colitis induced by IL-10 KO T cells (Fig. 2 B). The
CD45RBhi population showed no disease-protective effect
in the colon, and the small but significant reduction in pa-
thology observed in the cecum was significantly less (P  
0.05) than that mediated by the CD45RBlow population.
Using cells from WT and IL-10 KO mice expressing dif-
ferent allotypes of CD45, we were able to track the donor
origin of the CD4  cells in the recipients. Although T cells in
colonic sections from diseased RAG KO mice were mainly
of IL-10 KO origin, comparable tissues of mice receiving IL-
10 KO cells plus infected WT CD4  CD45RBlow  cells
showed a marked reduction in the number of IL-10 KO cells
with a simultaneous presence of scattered T cells of WT ori-
gin (unpublished data). The dramatic reduction in the num-
bers of T cells in the intestine of IL-10 KO CD4 cell recipi-
ents after cotransfer with infected WT CD45RBlow cells was
even further evident when colonic sections were stained for
CD3  cells (Fig. 3, G and H). These data suggest that
CD45RBlow CD4  cells from infected WT mice regulate the
recruitment and/or expansion of pathogenic IL-10 KO T
cells in the intestine and are in accordance with findings by
Figure 2. CD45RBlow CD4  cells from H. hepaticus–infected WT mice
protect RAG KO animals from colitis induced by IL-10 KO CD4  cells
plus bacterial infection. (A) H. hepaticus–infected RAG KO mice (solid
bars) were inoculated with CD4  cells from infected IL-10 KO mice and
CD4  cells from naive or infected WT mice as indicated (4   105 of each
population). Intestinal pathology was analyzed 4 wk later. Naive (open
bar) and infected RAG KO animals receiving no cells were included as
controls. Bars represent mean histology scores   SD of three mice per
group except for groups receiving WT cells alone, in which case, due to
limited cell numbers, only two mice per group were used. Similar results
were seen in ascending colon (although histology scores were lower) and
when disease was induced by the transfer of CD4  cells from naive IL-10
KO mice (not depicted). (B) Infected RAG KO mice were given either
no cells or CD4  cells from infected IL-10 KO mice and CD4 ,
CD45RBhi CD4 , or CD45RBlow CD4  cells from infected WT mice as
indicated (4   105 of each population). Pathology in the cecum (solid
bars) and ascending colon (gray bars) were analyzed 4 wk later. Bars represent
mean histology scores   SD of six or seven mice per group pooled from
two separate experiments except for the group receiving IL-10 KO
CD4  cells plus infected WT CD4  cells (n   3), which was included in
only one of the experiments. Statistical significance was tested for groups
receiving IL-10 KO cells. *, P   0.05 compared with mice receiving
IL-10 KO cells alone.509 Kullberg et al.
Annacker et al. (11), in which colitis in SCID mice trans-
planted with CD45RBhi and CD45RBlow cells expressing dif-
ferent CD45 allotypes was studied.
Both CD25  and CD25  Subpopulations of CD45RBlow
CD4  Cells Protect against Bacteria-induced Colitis. To fur-
ther phenotype the disease-protective CD45RBlow CD4 
lymphocytes, we sorted CD25  and CD25  cells from this
population and asked whether these cells could inhibit coli-
tis. Two recent reports have demonstrated that CD25 
CD45RBlow CD4  cells from naive mice are superior to
the CD25  subpopulation in blocking CD45RBhi-induced
colitis in T cell–deficient mice (18, 19). Our experiments
using IL-10 KO CD4  cells plus H. hepaticus to induce dis-
ease indicate that the CD25  and CD25  populations pre-
vent disease to a similar degree when given at a 1:1 ratio
with the pathogenic cells. However, at an IL-10 KO
CD4 /WT CD45RBlow ratio of 3:1 or 9:1, the CD25 
CD45RBlow cells are more effective in blocking intestinal
inflammation than the CD25   subpopulation (Fig. 4).
Thus, when given with 3   105 IL-10 KO CD4  cells, 105
of the CD25  CD45RBlow WT cells were able to signifi-
cantly suppress pathology in both the cecum and the colon,
whereas the same number of cells of the CD25  subpopu-
lation conferred partial protection only in the cecum. Al-
though disease protection by the CD25  cells was com-
pletely lost at 3.3   104 cells, the CD25  cells still suppressed
inflammation at this dosage (Fig. 4).
CD25  and CD25  Treg Cells from Infected WT Mice
Block Colitis via an IL-10–dependent but TGF- –independent
Mechanism. To analyze whether IL-10/TGF-   are im-
portant mediators in blocking H. hepaticus–induced colitis,
infected RAG KO mice receiving pathogenic IL-10 KO
CD4  cells with disease-protective WT CD25  or CD25 
CD45RBlow CD4  cells were treated with control mAb,
anti–IL-10R, or anti–TGF-  at doses previously shown to
abrogate protection in the SCID IBD model (16–18). As
shown in Fig. 5 A, anti–IL-10R treatment completely ab-
rogated the disease-protective effect of both the CD25 
and the CD25  subpopulations of the CD45RBlow CD4 
cells. In contrast, anti–TGF-  did not significantly affect
the protection mediated by either population. These results
were confirmed in a separate experiment in which protec-
tion by both CD25  and CD25  CD45RBlow cells was
largely unaffected by anti–TGF-  treatment, even after the
Figure 3. Intestinal pathology of H.
hepaticus–infected RAG KO mice receiving
CD4   cells from IL-10 KO and WT
mice. (A–F) Representative cecal sections
of the infected RAG KO mice described in
Fig. 2 A receiving (A) no cells, (B) infected
IL-10 KO CD4  cells, (C) infected IL-10
KO CD4  cells plus infected WT CD4 
cells, (D) infected IL-10 KO CD4  cells
plus naive WT CD4  cells, (E) infected WT
CD4  cells alone, and (F) naive WT CD4 
cells alone. H&E staining. (G and H) Im-
munohistochemical staining for CD3  T
cells (arrows) in colonic sections of in-
fected RAG KO recipients receiving (G)
infected IL-10 KO CD4  cells alone and (H)
infected IL-10 KO CD4  cells plus infected
WT CD45RBlow CD4  cells. Bar, 200  m.510 Bacteria-induced Regulatory T Cells Suppress Colitis
amount of mAb was doubled to 4 mg/wk (Fig. 5 B).
Moreover, in agreement with previously published results
(16, 18), treatment with the same anti–TGF-  mAb re-
versed the protection of CD45RBhi reconstituted, unin-
fected RAG KO recipients mediated by CD45RBlow cells
from the MLNs of naive WT animals (unpublished data).
The possibility still existed that IL-10 derived from host
non-T cells plays a role in disease protection mediated by in-
fected WT cells in our model. Therefore, we performed cell
transfers into double RAG/IL-10 KO mice. As demon-
strated in single RAG KO recipients (Fig. 2 A), CD4  cells
from infected but not naive WT mice protected from colitis
induced by IL-10 KO CD4  cells plus H. hepaticus infection
also in these IL-10–deficient RAG KO mice (unpublished
data). This finding was supported by subsequent cell sorting
experiments demonstrating that the disease-protective cells
are found within the CD45RBlow CD4  population and that
their inhibitory effect is abrogated by treatment of the RAG/
IL-10 KO recipients with anti–IL-10R mAb (Fig. 6 A).
The disease-protective IL-10–secreting CD4  cells were
shown to develop independently of IL-4, as CD4  cells iso-
lated from H. hepaticus–infected IL-4 KO mice were as potent
as CD4  cells from infected WT mice in blocking disease (Fig.
6 B). Treatment with anti–IL-10R completely abolished this
protective effect (Fig. 6 B), indicating that IL-4 is not required
for either the development or the effector function of the dis-
ease-protective cells. Together, these results suggest that T
cell–derived IL-10, but not TGF-  or IL-4, is important for
protecting RAG KO mice against colitis induced by patho-
genic cells plus H. hepaticus infection, and that the disease-pro-
tective cells are distinct from conventional Th2 cells.
Responsiveness of Disease-protective CD45RBlow CD4  Treg
Cells to Bacterial Ag. Our results clearly show that CD4 
cells must be obtained from H. hepaticus–infected IL-10–
competent mice to confer protection from colitis triggered
by this bacterium. These data could imply that the infec-
tion per se results in a selective expansion of a particular
Treg population (for example, CD45RBlow cells) and/or
that the disease-protective cells specifically recognize and
respond to Helicobacter Ag. To examine the first possibility,
MLN CD4  cells from naive and infected WT mice were
analyzed for their CD45RB and CD25 expression. In mul-
tiple experiments using mice at various time points after in-
fection, no difference was observed in CD45RB and CD25
expression of MLN CD4  cells between naive and H. he-
paticus–infected animals (unpublished data). In addition,
CD45RBlow CD4  cells from uninfected WT mice were
unable to prevent intestinal inflammation in infected RAG
KO mice reconstituted with IL-10 KO cells (Fig. 7 A).
Similarly, CD25  CD4  cells from infected but not naive
WT animals inhibited disease (unpublished data).
Additional evidence for Ag specificity came from experi-
ments using naive WT CD45RBhi cells to induce disease in
uninfected RAG KO recipients. Despite the inability of
CD45RBlow CD4  cells from naive WT mice to protect
against Helicobacter-triggered colitis in IL-10 KO T cell recon-
stituted RAG KO mice, as previously reported (7, 15), these
cells inhibited the wasting disease (Fig. 7 B) and colitis (Fig. 7
C, top) induced in uninfected RAG KO animals by the trans-
fer of naive WT CD45RBhi CD4  cells. However, if the re-
cipients of the naive WT CD45RBhi cells were first infected
with H. hepaticus, disease protection was again only observed
when using WT CD45RBlow cells from H. hepaticus–primed
mice (Fig. 7 C, bottom). These results suggest that the MLNs
of H. hepaticus–infected but not naive WT mice contain Treg
cells capable of protecting against Helicobacter-induced colitis.
To further address whether H. hepaticus–reactive Treg
lymphocytes exist within the CD45RBlow CD4 population,
we used an in vitro model in which the suppressive effect of
Treg cells on a responder IL-10 KO CD4  cell population
was examined. Using this system, infected but not naive WT
CD45RBlow CD4  cells inhibited IFN-  production by IL-
10 KO CD4  cells in an H. hepaticus Ag–specific manner
(Fig. 8 A). In addition, the infected WT CD45RBlow CD4 
Figure 4. CD25  CD45RBlow as well as CD25  CD45RBlow CD4 
cells from infected WT mice protect RAG KO mice against colitis. In-
fected RAG KO mice were given either no cells or 3   105 CD4  cells
from infected IL-10 KO mice either alone or with 3   105 CD45RBlow
CD4  cells, 3   105, 105, or 3.3   104 CD25  CD45RBlow, or CD25 
CD45RBlow CD4  cells from infected WT mice as indicated. (A) Pa-
thology in the cecum and (B) ascending colon was analyzed 4 wk later.
 , an individual mouse; —, the average for each group. Data shown are
pooled from two separate experiments. *, P   0.05; **, P   0.01; ***,
P   0.001 compared with infected mice receiving IL-10 KO cells alone.511 Kullberg et al.
cells were shown to produce IL-10 after stimulation with
SHelAg plus IL-2 as measured by both ELISA and intracel-
lular cytokine staining, a response not detected from compa-
rable cell populations from naive mice (Fig. 8, B and C). As
expected, CD45RBlow cells from both naive and infected
WT mice produced IL-10 in response to anti-CD3 plus IL-2
(Fig. 8 B). Taken together, our results argue that the mecha-
nism by which CD4  cells from infected WT mice block
colitis involves the production of IL-10 from CD45RBlow
CD4  Treg cells induced by exposure to H. hepaticus.
Discussion
In this study, we show that H. hepaticus infection induces
a population of CD4  CD45RBlow Treg cells that inhibit
the development of colitis triggered by this gram-negative
bacterium. Based on their absence in uninfected animals
and their restimulation in vitro by H. hepaticus Ag, we ar-
gue that these cells are directed against bacterial compo-
nents and may be analogous to Treg cells that prevent the
host from mounting pathologic responses to gut flora.
The concept that Treg cells are responsible for the preven-
tion of IBD in normal hosts has emerged from a number of
previous studies (7, 8, 30). Perhaps most pertinent are the find-
ings of Powrie and co-workers (7, 15), who used a CD4/
SCID transfer model to demonstrate the existence in normal
mice of CD45RBlow CD4  Treg cells that inhibit intestinal in-
flammation in CD45RBhi reconstituted SCID mice. Al-
though the presence of bacterial flora was found to be essential
for driving the CD45RBhi-induced pathogenic immune re-
sponse (9, 10), the above studies did not address the Ag speci-
ficity of the disease-protective CD45RBlow Treg population.
We have adapted the CD4/SCID model using H. hepaticus–
infected T cell–deficient mice as recipients to examine this is-
sue. The cells we found to protect from intestinal inflamma-
tion in this model differed from those described in the studies
of Powrie and co-workers in that their frequency was higher
Figure 5. CD25  CD45RBlow and CD25 
CD45RBlow CD4  cells from infected WT
mice block colitis via an IL-10–dependent
but TGF- –independent mechanism.
Infected RAG KO mice were given either
no cells or CD4  cells from infected IL-10
KO mice and CD25   CD45RBlow  or
CD25  CD45RBlow  CD4  cells from in-
fected WT mice (3   105 of each population)
and treated with control mAb, anti–IL-10R
(both at 1 mg/wk), or anti–TGF-  as indi-
cated. (A) In the first experiment, mice
were given 2 mg of anti–TGF-  per wk for 4
wk, (B) and in the second experiment, they
were given 4 mg of anti–TGF-  per wk for
2 wk before analysis.  , the cecal histology
score from an individual mouse; —, the
average for each group. Similar results, al-
though lower histology scores, were seen
for the ascending colon where CD25  cell
recipients treated with control or anti–TGF-  mAb displayed indistinguishable scores in B. In A, anti–IL-10R–treated groups had P values of
 0.01 and  0.05 compared with control mAb–treated groups, whereas scores for mice given anti–TGF-  were not significantly different from
those receiving control mAb. Similar results were seen in B except that it was not technically possible to perform Mann-Whitney U test statistics
on recipients of CD25  cells due to identical scores of all mice receiving control mAb.
Figure 6. T cell–derived IL-10 mediates the disease-protective effect of
WT CD45RBlow CD4  cells. (A) Infected RAG/IL-10 double deficient
mice were given either no cells or infected IL-10 KO CD4  cells and
infected WT CD4  CD45RBlow cells as indicated (4   105 of each
population) and then treated with control mAb or anti–IL-10R mAb for
4 wk. Bars represent mean cecal histology scores   SD of three mice per
group. (B) Infected RAG KO mice (solid bars) were inoculated with
CD4  cells from infected IL-10 KO, WT, and IL-4 KO mice as indicated
(3   105 of each population) and then treated with control mAb or anti–
IL-10R mAb for 4 wk. Naive (open bar) and infected RAG KO animals
receiving no cells were included as controls. Bars represent mean cecal
histology scores   SD of three mice per group from one representative
experiment out of two performed. Statistical significance was tested for
groups receiving IL-10 KO cells. *, P   0.05 compared with mice receiving
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in the CD25  compared with the CD25  CD45RBlow CD4
subpopulation and their disease-protective function was
blocked by anti–IL-10R but not anti–TGF-  treatment.
The original Treg populations described by Sakaguchi
and co-workers (31, 32), and subsequently by other groups
(18, 33–35), occur naturally in naive animals and express
CD25 as a defining phenotypic marker. These conven-
tional CD25  cells are generated in the thymus (36, 37) and
may require exposure to their target Ag to maintain their
function as suppressors of autoimmune disease (38). Our
observation that the cells that protect from H. hepaticus–
induced colitis are enriched within the CD25  CD45RBlow
subset and are not present in uninfected mice argues that
such cells, rather than being endogenous, represent a mem-
ory population resulting from previous exposure to exoge-
nous bacterial Ag. Although less suppressive than the
CD25  CD45RBlow subset, the CD25  subpopulation also
possessed significant activity in our model. These disease
inhibitory CD25  CD45RBlow cells may differ from those
Figure 7. CD45RBlow CD4  cells from naive WT mice are unable to
protect RAG KO recipients from colitis induced by pathogenic T cells
plus H. hepaticus infection. (A) Infected RAG KO mice were given either
no cells or CD4  cells from infected IL-10 KO mice and CD45RBlow
CD4  cells from naive or infected WT mice (4   105 of each population),
and tissues were analyzed 4 wk later. Bars represent mean cecal (solid
bars) and colonic (gray bars) histology scores   SD of three mice per
group. (B and C) Uninfected or H. hepaticus–infected (Hh-inf.) RAG KO
mice were given either no cells or CD45RBhi CD4  cells from naive WT
mice and CD45RBlow CD4  cells from naive or infected WT mice (3  
105 of each population). Body weights were measured weekly and tissues
were analyzed after 4 and 7.5 wk for infected and uninfected recipients,
respectively. (B) Results shown represent mean body weights (expressed
as a percentage of the weight 2 d after cell transfer) of four mice per group
from the uninfected RAG KO recipients. No difference in body weight
was observed between the four groups of infected recipients over the
4-wk time period that these groups were being followed (not depicted).
(C) Bars represent mean cecal (solid bars) and colonic (gray bars) histology
scores   SD of three or four mice per group. Statistical significance was
tested for groups receiving pathogenic cells. *, P   0.05 compared with
mice receiving infected IL-10 KO CD4  cells alone (A) or naive WT
CD45RBhi CD4  cells alone (C).
Figure 8. CD45RBlow CD4  cells from infected WT mice inhibit IFN- 
production by IL-10 KO CD4  cells and produce IL-10 after in vitro
stimulation with SHelAg. (A) Responder CD4  cells from infected IL-10
KO mice were cultured with APC, SHelAg, and indicated numbers of
CD45RBlow CD4  cells from naive ( ) or infected ( ) WT mice. IFN- 
was measured in 72-h supernatants. (B) CD45RBlow CD4  cells from
naive ( ) or infected ( ) WT mice were cultured with IL-10–deficient
APC and indicated Ag. IL-10 was measured in 72-h supernatants. No
IFN- , IL-4, or IL-5 was detected in cultures stimulated with SHelAg
plus IL-2. (C) CD45RBlow cells from naive or infected WT mice were
cultured with IL-10–deficient APC and SHelAg plus IL-2. After removal
of supernatants at 72 h, IL-2 was added for an additional 18 h before cells
were stimulated with PMA plus ionomycin and analyzed for the expression
of IL-10 and IFN-  by intracellular staining. The FACS® dot plots shown
are gated on CD4  cells. In the same assay, the cells were negative for
intracellular IL-4. The results shown in A–C are representative of two or
three experiments performed.513 Kullberg et al.
described by Read et al. (18) and Annacker et al. (19), as no
protection was observed when CD25  cells from unin-
fected animals were tested in our model. One possibility is
that the suppression obtained is due to recently activated
IL-2R  H. hepaticus–specific cells arising within the CD25 
CD45RBlow population and perhaps diluted by the pres-
ence of large numbers of conventional Treg cells.
Although disease protection in the SCID transfer model
of IBD is abrogated by treatment with mAb against TGF- ,
the H. hepaticus–induced Treg cells do not appear to block
colitis through a mechanism involving this cytokine. Even
though we have used an mAb different from that of Powrie
and co-workers (16, 18), 30  g/ml of this reagent was
shown to efficiently neutralize at least 2.5 ng of TGF-  in
vitro (unpublished data). Furthermore, we confirmed that
the mAb we used abrogated CD45RBlow-mediated disease
protection in the SCID IBD model. Finally, the same mAb
has been shown by others to block TGF- –mediated sup-
pression of IBD in the trinitrobenzene sulfonic acid colitis
model (39). Thus, we consider it highly unlikely that the
difference in TGF-  dependency observed between the H.
hepaticus–induced and the CD4/SCID colitis models is due
to incomplete neutralization by the mAb used. Instead, as
H. hepaticus induces a more rapid onset of, and a more se-
vere colitis in, T cell reconstituted RAG KO mice than
that of the SCID model (40), it is possible that a different
type of Treg cell that preferentially secretes high amounts
of IL-10 rather than TGF-  is required to prevent H. he-
paticus–triggered disease. In this respect, our Treg cells
more closely resemble the IL-10–producing Ag-induced
Tr1 cells that develop in the presence of IL-10 (22, 23) and
are thought to block colitis through the production of this
cytokine (22), as well as the recently described IL-10–pro-
ducing Treg cells shown to develop after in vitro Ag stimu-
lation with vitamin D3 plus dexamethasone (24). Based on
their lack of dependence on TGF- , the H. hepaticus–
induced regulatory cells appear to be distinct from the Th3
cells implicated in oral tolerance (41).
Perhaps the most intriguing finding of this study is that
the Treg cells that protect from H. hepaticus–induced colitis
appear to be primed by H. hepaticus Ag. This conclusion is
based both on the requirement for H. hepaticus infection of
the regulatory cell donors and on the ability of the disease-
protective populations to produce IL-10 in response to spe-
cific Ag stimulation. The ability of cells from an infected
donor to suppress intestinal inflammation triggered by the
same pathogen was previously documented in a model of
Toxoplasma gondii–induced ileitis (42). Although the phe-
notype of the protective intraepithelial lymphocytes was
not determined, the cells involved appear to be distinct
from those characterized here, as their disease inhibitory ef-
fect was abrogated by anti–TGF-  treatment. Moreover, in
contrast to the situation in the H. hepaticus model, the T.
gondii–infected donors from which the ileitis-preventing
cells were derived are not protected against disease. To
date, little information is available regarding the Ag speci-
ficity of Treg cells that protect from various pathogenic im-
mune responses. Data from an elegant study by Seddon and
Mason (38) on autoimmune thyroiditis have suggested that
it is the presence of the peripheral autoantigen that main-
tains Treg cells in the periphery, as CD4  cells from the
spleen and LN of athyroid hosts were unable to protect
against thyroiditis but did block the development of diabe-
tes. Similarly, based on the findings reported here, it is
tempting to speculate that the most efficient Treg cells pro-
tecting against bacteria-driven colitis require priming by
bacterial Ag for their generation. One may infer from data
by Singh et al. (43) that flora plays a role in the generation
of disease-protective CD45RBlow cells also in the SCID
IBD model, as at lower cell numbers, CD45RBlow cells
from SPF-reared mice display a higher capacity to protect
CD45RBhi reconstituted SCID mice from colitis compared
with CD45RBlow cells isolated from GF animals. Thus, al-
though Treg cells with no experience of bacterial Ag can
exhibit protective activity, bacterial priming may result in
much more effective disease suppression. Clearly, studies
using Treg cells with defined specificities, e.g., Treg cell
clones, are critical to formally establish the Ag specificity of
the cells protecting from colitis in our model. However,
such studies are technically difficult due to the poor prolif-
erative capacity of Treg cells, and to date, our attempts to
generate such clones have been unsuccessful.
The detailed mechanism by which Treg cells protect from
colitis remains to be elucidated. Treg cells do not appear to
prevent the initial activation of responder T cells, as normal
up-regulation of early activation markers on the latter popula-
tion is observed in the presence of Treg cells (44). Instead, the
responder cells undergo cell cycle arrest at the G0/G1 stage
(44). Moreover, in vivo studies have shown that the cotrans-
fer of CD45RBhi and CD45RBlow cells limit the number of
pathogenic CD45RBhi cells present in SCID or RAG KO re-
cipients (11, 17, 19). Consistent with these findings, we ob-
served reduced numbers of IL-10 KO T cells infiltrating the
intestines of H. hepaticus–infected RAG KO recipients pro-
tected from colitis by the cotransfer with CD4  cells from in-
fected WT mice. The hypothesis that Treg cells limit the de-
velopment of pathogenic Th1 cells is also supported by our
failure to detect IFN-  in SHelAg-stimulated total MLN cells
(20), or CD45RBlow cultures (Fig. 8 B), from infected WT
mice, even in the presence of neutralizing anti–IL-10 mAb
(unpublished data). One explanation for this finding could be
that Treg lymphocytes induce death of pathogenic cells per-
haps through competition for growth-promoting cytokines.
Another possible explanation for this impaired expansion of
pathogenic cells is that disease-protective Treg cells, through
their production of IL-10, prevent the activation of cells of
the innate immune system (45, 46) such as DCs, as has been
previously suggested in studies on the effects of anti-OX40L
mAb treatment on colitis in the SCID IBD model (47). A
role for Treg cell–produced IL-10 in this suppression of the
innate immune response is supported by the observation of
spontaneous enterocolitis in mice with a cell type–specific
disruption of the Stat3 gene in macrophages and neutrophils
that renders these cells IL-10 unresponsive (48).
A major question raised by this study is whether gut
flora–reactive Treg cells, similar to those described here,514 Bacteria-induced Regulatory T Cells Suppress Colitis
prevent the appearance of IBD in humans. Evidence in
support of this mechanism comes from studies demonstrat-
ing peripheral T cell tolerance in the intestine toward resi-
dent autologous gut flora, a state that is broken in active
IBD (49) and appears to be mediated by bacterial Ag–reac-
tive CD4  T cells secreting IL-10 and TGF-  (50). Addi-
tional analysis should help establish whether the cells in-
volved are phenotypically analogous to the Treg cells
studied here. A major implication of these human and mu-
rine studies is that IBD may result from a defect in the de-
velopment or function of bacteria-specific Treg cells. If so,
treatments that augment the generation or function of such
cells may offer an approach for therapeutic intervention in
these intestinal inflammatory diseases.
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